Reduced serum levels of the pro-resolving lipid mediators resolvin D1 and lipoxin A4 in schizophrenia

TomAlright, here's something on my mind: Reduced serum levels of the pro-resolving lipid mediators resolvin D1 and lipoxin A4 in schizophrenia. Where do you stand on this?

CarolThe idea that your body literally loses the ability to put out its own fire while you're still burning down inside is pretty grim to sit with. It shifts the blame away from just "chemical imbalance" and onto a system that can't self-repair. That raises some tough questions about how long people go untreated before their biology just gives up trying.

TomBut wait, saying the body gives up implies they tried hard and failed. This is just a state where those specific signals aren't there at all, like the smoke detector battery died rather than the alarm breaking. We shouldn't anthropomorphize a missing protein level into a moral failure of the immune system.

CarolYou’re stripping the context right out of it. Those mediators aren’t static batteries; they’re active signals that tell cells when to stop inflaming, so calling this just a "missing protein" ignores that the resolution process itself is broken. For anyone living with chronic psychosis, that means their brain is stuck in a low-grade fight mode without ever getting the memo to lay down arms.

TomCalling it "fight mode" paints a picture of constant war, but the data just shows lower RvD1 and LXA4 levels. That’s a gap between the headline finding and the lived reality we’re assuming. Before we talk about brains being stuck, we need to know if that absence actually drives the symptoms or just sits alongside them.

CarolThat distinction matters because correlation isn't causation, but it doesn't mean we ignore the mechanism. If the body can't clear neuroinflammation, the damage accumulates over time regardless of whether it causes every symptom directly. We are looking at a biological floor dropping out under the patient, not just a side effect sitting next to the problem.

TomYou're leaning on that word "floor" again, which sounds dramatic but skips over why the signal vanished in the first place. I'm not arguing the inflammation isn't real, just that we don't yet know if these low levels are the cause or simply the residue left behind after years of illness. Without knowing that link, we're guessing at a repair strategy based on a snapshot.

CarolLeaving it at “residue” misses the point that unresolved inflammation actively erodes cognitive function, so even if these markers started low, keeping them low prevents recovery. The clinical risk isn’t just having the baseline; it’s staying trapped in a cycle where the brain keeps taking damage without any off switch.

TomStaying trapped in a cycle assumes the door is locked from the outside, but we haven't even checked the key yet. I’m not doubting the erosion happens, just pointing out that prescribing a fix based purely on a snapshot feels premature until we understand what knocked those levels down in the first place.

CarolAsking for the key before acknowledging the lock exists is backwards. The immediate danger is that current treatments target the hallucinations while leaving the underlying inflammatory burden completely unaddressed, meaning the brain keeps chipping away even when the patient seems stable. Until we verify if boosting those resolvin levels reverses the cognitive decline, everyone is managing a slow burn with a wet cloth.

TomThe wet cloth image works, but it treats the fire as permanent when we might be able to turn off the stove. I'm pushing back on the assumption that the cognitive chip is irreversible just because the meds miss the inflammation; that's a leap from "unaddressed" to "doomed." We need proof that reversing the burn stops the erosion before we start designing rescue plans around it.

CarolFraming it as "proof that reversing the burn stops the erosion" sidesteps the actual timeline, since cognitive decline often plateaus long before we intervene. By waiting for definitive reversal data, we leave patients continuing to lose functional capacity year after year while the inflammation runs unchecked.

TomWaiting for perfect reversal data ignores that early intervention usually buys more function than late-stage cleanup ever will. But calling the decline a plateau assumes the damage has stopped progressing when it hasn't, and that changes who exactly gets triaged into these experimental tracks right now.

CarolCalling the decline a plateau is a dangerous guess, because the loss compounds silently long before it becomes obvious in daily tasks. Triaging patients without that longitudinal view means we're prioritizing people based on visible symptoms rather than active neural damage, which leaves the quiet ones sliding further down while we argue about methodology.

TomThat last bit about the "quiet ones" sliding down is actually the strongest argument you've made all day. I'll concede that visible symptom triage misses the silent erosion happening under the surface. Let's stop spinning our wheels on methodology and focus on whether targeting RvD1 can catch those invisible losses before they become permanent.

CarolTargeting RvD1 sounds promising on paper, but without knowing if the body can synthesize enough to matter, we’re chasing a ghost. The real issue is that current care focuses on halting psychosis, not repairing the neural tissue that’s been slowly stripped away by years of unchecked inflammation. We need to see if boosting those specific mediators actually restores cognitive function, otherwise we’re just adding another pill to a regimen that hasn’t fixed anything fundamental.

TomYou’re stuck on the synthesis bottleneck when the bigger mystery is why the production machinery shut down in the first place. If we don’t figure out what initially suppressed those RvD1 levels, adding more exogenous lipids is just pouring water into a bucket with holes we haven’t mapped yet. The whole field needs to answer why the resolution system failed before anyone claims they know how to restart it.